Be part of the knowledge.™

Spotlight On ATTR-CM

Welcome to Spotlight On ATTR-CM, your go-to source for the latest research, diagnostic advancements, and therapeutic strategies in transthyretin amyloid cardiomyopathy (ATTR-CM). Join leading cardiologists and researchers as they share their insights on this intricate condition to enhance patient care and outcomes.

0

LikeLikedUnlike

1-15 of 29

Redefining ATTR Treatment: Key Mechanisms and Emerging Data
Heart Matters
Redefining ATTR Treatment: Key Mechanisms and Emerging Data
- Ahmad Masri, MD, MS
  Peer
Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
Heart Matters
Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
- Kevin Alexander
  Peer
Treating ATTR-CM Early: A Shift From Reactive to Strategic Care
Heart Matters
Treating ATTR-CM Early: A Shift From Reactive to Strategic Care
- Quan Bui, MD
  Peer
Advancing Diagnosis of Transthyretin Cardiac Amyloidosis in Underserved Populations
Heart Matters
Advancing Diagnosis of Transthyretin Cardiac Amyloidosis in Underserved Populations
Exploring Tafamidis Survival Data in Elderly Patients with ATTR-CM
AudioAbstracts
Exploring Tafamidis Survival Data in Elderly Patients with ATTR-CM
- Hallie Blevins, PhD
  Peer
Understanding Diagnostic Gaps Among Medicare Patients with ATTRwt-CM
Heart Matters
Understanding Diagnostic Gaps Among Medicare Patients with ATTRwt-CM
advertisement
ATTR-CM Trials Revisited: A Broader View of Treatment Benefit
Heart Matters
ATTR-CM Trials Revisited: A Broader View of Treatment Benefit
From HCM to ATTR-CM: Rethinking Unexplained Hypertrophy
AudioAbstracts
From HCM to ATTR-CM: Rethinking Unexplained Hypertrophy
- Hallie Blevins, PhD
  Peer
Managing Concomitant Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Evolving Care Strategies
AudioAbstracts
Managing Concomitant Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Evolving Care Strategies
- Marlene Mimi Maeusli, PhD.
  Peer
Diagnostic Gaps in ATTR-CM: Insights from a Multispecialty Survey in France
Heart Matters
Diagnostic Gaps in ATTR-CM: Insights from a Multispecialty Survey in France
ATTR-CM Care: Impact of Vutrisiran on Survival and Cardiovascular Events
Heart Matters
ATTR-CM Care: Impact of Vutrisiran on Survival and Cardiovascular Events
- Ryan Quigley
  Peer
Timely ATTR-CM Diagnosis: Addressing Social Determinants of Health
Heart Matters
Timely ATTR-CM Diagnosis: Addressing Social Determinants of Health
- Kevin Alexander, MD
  Peer
advertisement
Equitable Care for ATTR-CM: Improving Early Diagnosis in High-Risk Groups
Heart Matters
Equitable Care for ATTR-CM: Improving Early Diagnosis in High-Risk Groups
- Kevin Alexander, MD
  Peer
Translating Patisiran’s 6-Minute Walk Test Gains into Real-Life Impact in ATTR-CM
Heart Matters
Translating Patisiran’s 6-Minute Walk Test Gains into Real-Life Impact in ATTR-CM
Staging the Benefit: Tafamidis Outcomes in ATTR-CM Depend on Timing
Heart Matters
Staging the Benefit: Tafamidis Outcomes in ATTR-CM Depend on Timing

Program Chapters

Segment Chapters

Playlist:

Recommended